{"doc_id": "33171431", "type of study": "Therapy", "title": "", "abstract": "Expressive writing to combat distress associated with the COVID-19 pandemic in people with inflammatory bowel disease (WriteForIBD): A trial protocol.\nA large proportion of patients with inflammatory bowel disease (IBD) receive immunosuppressive medication, may be at higher risk of complications if they contract SARS-CoV-2 virus, and therefore report high levels of COVID-19-related distress.\nThis trial will evaluate a brief, evidence-based, online, group-based expressive writing intervention to reduce COVID-19-related distress in people living with IBD at the time of pandemic.\nA parallel double-blind randomised controlled trial will be conducted.\nOverall, up to 154 adult participants with IBD and mild-moderate distress will be recruited via patient organisations.\nParticipants will be allocated to the expressive writing intervention or an active control group.\nAll participants will complete questionnaires including measures of distress, quality of life, resilience, self-efficacy, social support and disease activity before and after the intervention (1\u00a0week) and at 3\u00a0months post-intervention.\nThe expressive writing group will participate in the evidenced-based 4-day writing program adapted from Pennebaker and Beall, 1986.\nThe active control group will write about untherapeutic topics provided by researchers.\nStatistical analysis will be carried out on an intention-to-treat basis and will involve linear mixed effects models.\nIf successful, this simple intervention may bring personal and societal benefits, particularly because it is low cost, can be easily implemented online, ensuring social distancing, and be made widely available, during future disasters and to help with trauma-related distress in IBD.\nTRIAL REGISTRATION : The trial has been prospectively registered in the Australian New Zealand Trial Registry - ACTRN12620000448943p.\nCopyright \u00a9 2020 Elsevier Inc. All rights reserved.\n", "Evidence Map": {"Enrollment": [{"term": "COVID-19 pandemic", "negation": "affirmed", "UMLS": {}, "start": 58, "end": 75}, {"term": "inflammatory bowel disease", "negation": "affirmed", "UMLS": {}, "start": 91, "end": 117}, {"term": "IBD", "negation": "affirmed", "UMLS": {}, "start": 163, "end": 166}, {"term": "adult", "negation": "affirmed", "UMLS": {}, "start": 20, "end": 25}, {"term": "IBD", "negation": "affirmed", "UMLS": {}, "start": 44, "end": 47}, {"term": "mild-moderate distress", "negation": "affirmed", "UMLS": {}, "start": 52, "end": 74}], "Comparison Results": [], "Study Arm 1 Results": [], "Study Arm 2 Results": [], "Hypothesis": []}, "Sentence-level breakdown": [{"Section": "TITLE", "Text": "Expressive writing to combat distress associated with the COVID-19 pandemic in people with inflammatory bowel disease ( WriteForIBD ) : A trial protocol .", "Evidence Elements": {"Participant": [{"term": "COVID-19 pandemic", "negation": "affirmed", "UMLS": {}, "start": 58, "end": 75}, {"term": "inflammatory bowel disease", "negation": "affirmed", "UMLS": {}, "start": 91, "end": 117}], "Intervention": [{"term": "Expressive writing", "negation": "affirmed", "UMLS": {}, "start": 0, "end": 18, "has_relation": "N/A"}], "Outcome": [], "Observation": [], "Count": []}, "Evidence Propositions": []}, {"Section": "OBJECTIVE", "Text": "A large proportion of patients with inflammatory bowel disease ( IBD ) receive immunosuppressive medication , may be at higher risk of complications if they contract SARS-CoV-2 virus , and therefore report high levels of COVID-19-related distress .", "Evidence Elements": {"Participant": [], "Intervention": [], "Outcome": [], "Observation": [], "Count": []}, "Evidence Propositions": []}, {"Section": "OBJECTIVE", "Text": "This trial will evaluate a brief , evidence-based , online , group-based expressive writing intervention to reduce COVID-19-related distress in people living with IBD at the time of pandemic .", "Evidence Elements": {"Participant": [{"term": "IBD", "negation": "affirmed", "UMLS": {}, "start": 163, "end": 166}], "Intervention": [{"term": "brief , evidence-based , online , group-based expressive writing intervention", "negation": "affirmed", "UMLS": {}, "start": 27, "end": 104, "has_procedure": [{"text": "expressive writing intervention", "maps_to": "C0886296:intervention", "start": 46, "end": 77}], "has_relation": "N/A"}], "Outcome": [{"term": "COVID-19-related distress", "negation": "affirmed", "UMLS": {}, "start": 115, "end": 140}], "Observation": [{"term": "reduce", "negation": "affirmed", "UMLS": {}, "start": 108, "end": 114}], "Count": []}, "Evidence Propositions": []}, {"Section": "METHODS", "Text": "A parallel double-blind randomised controlled trial will be conducted .", "Evidence Elements": {"Participant": [], "Intervention": [], "Outcome": [], "Observation": [], "Count": []}, "Evidence Propositions": []}, {"Section": "METHODS", "Text": "Overall , up to 154 adult participants with IBD and mild-moderate distress will be recruited via patient organisations .", "Evidence Elements": {"Participant": [{"term": "adult", "negation": "affirmed", "UMLS": {}, "start": 20, "end": 25}, {"term": "IBD", "negation": "affirmed", "UMLS": {}, "start": 44, "end": 47}, {"term": "mild-moderate distress", "negation": "affirmed", "UMLS": {}, "start": 52, "end": 74}], "Intervention": [], "Outcome": [], "Observation": [], "Count": []}, "Evidence Propositions": []}, {"Section": "METHODS", "Text": "Participants will be allocated to the expressive writing intervention or an active control group .", "Evidence Elements": {"Participant": [], "Intervention": [{"term": "expressive writing intervention", "negation": "affirmed", "UMLS": {}, "start": 38, "end": 69, "has_procedure": [{"text": "expressive writing intervention", "maps_to": "C0886296:intervention", "start": 0, "end": 31}], "has_relation": "N/A"}, {"term": "active control", "negation": "affirmed", "UMLS": {}, "start": 76, "end": 90, "has_relation": "N/A"}], "Outcome": [], "Observation": [], "Count": []}, "Evidence Propositions": []}, {"Section": "METHODS", "Text": "All participants will complete questionnaires including measures of distress , quality of life , resilience , self-efficacy , social support and disease activity before and after the intervention ( 1 week ) and at 3 months post-intervention .", "Evidence Elements": {"Participant": [], "Intervention": [], "Outcome": [{"term": "distress", "negation": "affirmed", "UMLS": {}, "start": 68, "end": 76}, {"term": "quality of life", "negation": "affirmed", "UMLS": {}, "start": 79, "end": 94}, {"term": "resilience", "negation": "affirmed", "UMLS": {}, "start": 97, "end": 107}, {"term": "self-efficacy", "negation": "affirmed", "UMLS": {}, "start": 110, "end": 123}, {"term": "social support", "negation": "affirmed", "UMLS": {}, "start": 126, "end": 140}, {"term": "disease activity", "negation": "affirmed", "UMLS": {}, "start": 145, "end": 161}], "Observation": [], "Count": []}, "Evidence Propositions": []}, {"Section": "METHODS", "Text": "The expressive writing group will participate in the evidenced-based 4-day writing program adapted from Pennebaker and Beall , 1986 .", "Evidence Elements": {"Participant": [], "Intervention": [{"term": "expressive writing", "negation": "affirmed", "UMLS": {}, "start": 4, "end": 22, "has_relation": "N/A"}, {"term": "evidenced-based 4-day writing program", "negation": "affirmed", "UMLS": {}, "start": 53, "end": 90, "has_relation": "N/A"}], "Outcome": [], "Observation": [], "Count": []}, "Evidence Propositions": []}, {"Section": "METHODS", "Text": "The active control group will write about untherapeutic topics provided by researchers .", "Evidence Elements": {"Participant": [], "Intervention": [{"term": "active control", "negation": "affirmed", "UMLS": {}, "start": 4, "end": 18, "has_relation": "N/A"}, {"term": "untherapeutic topics", "negation": "affirmed", "UMLS": {}, "start": 42, "end": 62, "has_relation": "N/A"}], "Outcome": [], "Observation": [], "Count": []}, "Evidence Propositions": []}, {"Section": "METHODS", "Text": "Statistical analysis will be carried out on an intention-to-treat basis and will involve linear mixed effects models .", "Evidence Elements": {"Participant": [], "Intervention": [], "Outcome": [], "Observation": [], "Count": []}, "Evidence Propositions": []}, {"Section": "CONCLUSIONS", "Text": "If successful , this simple intervention may bring personal and societal benefits , particularly because it is low cost , can be easily implemented online , ensuring social distancing , and be made widely available , during future disasters and to help with trauma-related distress in IBD .", "Evidence Elements": {"Participant": [], "Intervention": [], "Outcome": [], "Observation": [], "Count": []}, "Evidence Propositions": []}, {"Section": "UNKNOWN", "Text": "TRIAL REGISTRATION : The trial has been prospectively registered in the Australian New Zealand Trial Registry-ACTRN12620000448943p .", "Evidence Elements": {"Participant": [], "Intervention": [], "Outcome": [], "Observation": [], "Count": []}, "Evidence Propositions": []}, {"Section": "UNKNOWN", "Text": "Copyright \u00a9 2020 Elsevier Inc . All rights reserved .", "Evidence Elements": {"Participant": [], "Intervention": [], "Outcome": [], "Observation": [], "Count": []}, "Evidence Propositions": []}]}